Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5087806 | 0.97 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Water SCHEMBL8366271 | 0.97 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL5087218 | 0.97 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Iodide SCHEMBL5092148 | 0.97 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL29342 | 0.87 | TAAR1 (0.56) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL10503241 | 0.85 | TAAR1 (0.67) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL17714576 | 0.85 | TAAR1 (0.54) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL2351133 | 0.85 | KDM4E (0.57) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL11047140 | 0.85 | TAAR1 (0.54) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL465335 | 0.85 | KDM4E (0.57) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362494-B1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | EVONIK OPERATIONS GMBH (DE) | 2023-08-16 | — | — | EP | claimed |
| CN-106795261-B | Polyurethane catalysts based on salts of sulfur | 赢创运营有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-10570245-B2 | Polyurethane catalysts from sulfur based salts | EVONIK OPERATIONS GMBH (DE) | 2020-02-25 | — | — | US | claimed |
| US-10472459-B2 | Polyurethane catalysts from a sulfur based salts | EVONIK DEGUSSA GMBH (DE) | 2019-11-12 | — | — | US | claimed |
| EP-3362494-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | Evonik Degussa GmbH (DE) | 2018-08-22 | — | — | EP | claimed |
| EP-3207071-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | Evonik Degussa GmbH (DE) | 2017-08-23 | — | — | EP | claimed |
| WO-2017065832-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2017-04-20 | — | — | WO | claimed |
| US-20160229945-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2016-08-11 | — | — | US | claimed |
| WO-2016061068-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2016-04-21 | — | — | WO | claimed |
| US-20160102169-A1 | Polyurethane Catalysts from Sulfur Based Salts | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2016-04-14 | — | — | US | claimed |
| US-4312818-A | CATALYZED REACTION OF A PHENOL WITH A PHOSPHORUS HALIDE | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | claimed |
| EP-4637760-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024215862-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4419504-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002057286-A2 | 9-AMINO ERYTHROMYCIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002018321-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-5181988-A | Hypophosphorous acid or salt | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1993-01-26 | — | — | US | disclosed |
| EP-0199997-A2 | Process for preparing diaryl-pentaerythritol | ADEKA ARGUS CHEMICAL CO., Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036223-B2 | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | TSG101, TNFSF10, BCL2L10 | TAAR1 3276/4885SLC6A2 3773/4885SMN1; SMN2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.